Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells 8,273 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the transaction, the chief executive officer now directly owns 2,195,712 shares of the company’s stock, valued at approximately $109,785,600. This trade represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ultragenyx Pharmaceutical Trading Down 2.4 %

Ultragenyx Pharmaceutical stock opened at $45.78 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The firm has a market capitalization of $4.23 billion, a PE ratio of -7.08 and a beta of 0.56. The firm’s 50 day simple moving average is $50.47 and its 200 day simple moving average is $49.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.23) earnings per share. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 103.8% in the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after purchasing an additional 942,529 shares during the last quarter. Alkeon Capital Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock worth $167,301,000 after buying an additional 769,884 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Ultragenyx Pharmaceutical by 123.4% during the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock valued at $54,872,000 after buying an additional 545,600 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in Ultragenyx Pharmaceutical in the second quarter worth $17,468,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Ultragenyx Pharmaceutical by 63.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 830,375 shares of the biopharmaceutical company’s stock valued at $34,128,000 after acquiring an additional 323,280 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on RARE shares. HC Wainwright upped their price target on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.46.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.